Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Stopped This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.

Conditions

• Nonalcoholic Steatohepatitis
• Liver Cirrhosis
• Non-alcoholic Fatty Liver Disease

Interventions

• DRUG: Cenicriviroc

Sponsor

Tobira Therapeutics, Inc.